Shared Decision-Making Music Therapy With Esketamine for Treatment-Resistant Depression
Tanner Herb, Heeyoung Lee, Prabir Mullick, Joshua Palmer
The Journal for Nurse Practitioners August 10, 2026 DOI: 10.1016/j.nurpra.2026.105951 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Quality improvement project Peer reviewed |
|---|---|
| Sample size | 10 |
| Population | Adults with treatment-resistant depression at a private psychiatric clinic |
| Interventions | Esketamine Shared decision-making–guided music intervention |
| Duration | 4 months |
| Measures | Montgomery-Åsberg Depression Rating Scale, World Health Organization Quality of Life–BREF |
| Topics | Depression Esketamine |
| Key points | No significant overall changes in depressive symptoms or quality of life were observed, but health perception improved (P = .03). The authors suggest that individualized, shared decision-making–guided music intervention may enhance patient-centered care in treatment-resistant depression. |
Abstract
This quality improvement project examined the impact of shared decision-making–guided music intervention integrated into esketamine treatment on depressive symptoms and quality of life in 10 adults with treatment-resistant depression at a private psychiatric clinic. Over 4 months, patients collaborated with their providers to select and listen to music during each session. Depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale, and quality of life was assessed using the World Health Organization Quality of Life–BREF. Although no significant changes were observed overall, health perception improved ( P = .03). Findings suggest that individualized, shared decision-making–guided music intervention may enhance patient-centered care in treatment-resistant depression.
Citations in the library
Cites 5
- Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression New England Journal of Medicine October 4, 2023
- Psychedelics and music: neuroscience and therapeutic implications International Review of Psychiatry July 4, 2018
- An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression. Frontiers in Psychiatry November 24, 2021
- Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression Clinical Pharmacology & Therapeutics August 29, 2020
- Listening to music during intranasal (es)ketamine therapy in patients with treatment-resistant depression correlates with better tolerability and reduced anxiety Frontiers in Psychiatry January 23, 2024